Start with lactic acidosis, then reuse UniProt Q15119 as the stable protein anchor across project notes and exports.
CHEMBL2096665 Target Snapshot
Pyruvate dehydrogenase kinase · PROTEIN FAMILY · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Pyruvate dehydrogenase kinase shows late clinical disease relevance led by lactic acidosis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q15119. Start with lactic acidosis, then reuse UniProt Q15119 as the stable protein anchor across project notes and exports.
Pyruvate dehydrogenase kinase shows late clinical disease relevance led by lactic acidosis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with lactic acidosis because it currently carries late clinical support. Linked drugs include SODIUM DICHLOROACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial
Review this target as Pyruvate dehydrogenase kinase, mapped to UniProt Q15119. ChEMBL maps the protein component as [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial. Sequence length is 407 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Pyruvate dehydrogenase kinase as ChEMBL target CHEMBL2096665, mapped to UniProt Q15119. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Pyruvate dehydrogenase kinase is the right protein anchor across sources, using UniProt Q15119 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why lactic acidosis is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Pyruvate dehydrogenase kinase |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | Q15119 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial |
| UniProt Accession | Q15119 |
| Component Type | Protein |
| Sequence Length | 407 aa |
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial
How to read this target
Review this target as Pyruvate dehydrogenase kinase, mapped to UniProt Q15119. ChEMBL maps the protein component as [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial. Sequence length is 407 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Pyruvate dehydrogenase kinase shows late clinical disease relevance led by lactic acidosis. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with lactic acidosis because it currently carries late clinical support. Linked drugs include SODIUM DICHLOROACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL73068 | 8.15 | IC50 | 7.1 | Preclinical |
| CHEMBL74582 | 8.1 | IC50 | 8.0 | Preclinical |
| CHEMBL73204 | 8.08 | IC50 | 8.4 | Preclinical |
| CHEMBL3714823 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL3714889 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL3714928 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL3715044 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL3715049 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL3715072 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL3715313 | 8.0 | IC50 | 10.0 | Preclinical |
pChEMBL Value Distribution
Assay Landscape
Binding — 24 assays, 444 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 14 | 60 | 6.0 |
| protein format | 9 | 122 | 6.3 |
| assay format | 1 | 262 | 6.8 |
Functional — 1 assays, 8 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 1 | 8 | 5.9 |